CD40 and hypopituitarism: The appearance of hypophysitis in 3 checkpoint-treated patients (2 with ipilimumab, 1 with CD-40 monoclonal antibody) who did not have preexisting hypopituitarism suggests that indoximod helped to break tolerance after they were primed with the prior therapy months before going on this study.